Status: Recruiting
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in the first line with arsenic trioxide and all trans retinoic acid (ATO/ATRA) based regimens in Argentina.
Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Grupo Argentino de Tratamiento de la Leucemia AgudaUpdated: Jan 9, 2024Locations: 6
Eligibility criteria
Patients 18 years or older. [+3]
Presence of other concomitant active malignant tumors that require simultaneous... [+11]